TOBREX
What it isAminoglycoside inhibiting the 30S ribosomal subunit; Gram-negative and pseudomonal infection, inhaled in cystic fibrosis.
Why this oneBetter antipseudomonal activity than gentamicin, and the inhaled route delivers high airway concentrations with little systemic exposure.
What limits itNephrotoxicity and irreversible ototoxicity, so levels and function are monitored. Once-daily dosing exploits the post-antibiotic effect.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Cystic fibrosis, Pseudomonas aeruginosa | Adults & peds ≥6 yr | Four 28 mg capsules (112 mg) inhaled BID | 112 mg BID, 28 days on / 28 days off |
Renal Undefined (not studied in serum creatinine ≥2 mg/dL or BUN ≥40; monitor renal function)
Hepatic No adjustment needed (tobramycin not metabolized)
Dosage not adjusted by weight; each dose ≥6 hours apart
Pregnancy Aminoglycosides can cause fetal harm; systemic absorption after inhalation minimal; advise of potential risk
Lactation No data for inhaled form; systemic tobramycin present in human milk; monitor infant for loose/bloody stools and thrush
⚠ BOXED WARNINGS
Cost, est. cash$10–$500/bag or supply
Generic entry1984
Legacy pregnancy categoryD
Defining liabilityUsually well tolerated at replacement doses; excessive dosing can cause agent-specific metabolic or organ toxicity.
